Vivo Bio Tech (511509.BO) Stock Price

Vivo Bio Tech Price

CLOSED
14.88
​
Market closed

Over the last 12 years Vivo Bio Tech grew revenue by 10.5% annually, reaching 533.35 M INR. Earnings per share have grown at 33.9% per year over the last 11 years. For Vivo Bio Tech, the net margin of -3.2% is down versus 4.3% a few years ago.

Vivo Bio Tech stock price

Access this data via the Eulerpool API

Vivo Bio Tech business model & stock analysis

Vivo Bio Tech Ltd. engages in the provision of drug development and discovery services. The company is headquartered in Hyderabad, Telangana. The firm offers drug development and discovery services to pharmaceutical and biotech companies across the world. The firm offers services in the areas of In vivo and In vitro toxicity studies, pharmacological investigations, pharmacokinetic and toxicokinetic studies, genotoxicity screening, analytical services, and other. The company provides both regulatory and non-regulatory IND enabling preclinical development services. The company is engaged in screening and evaluating molecules for various pharmacological and therapeutic properties. Specifically for oncology, the Company provides designing and development of syngeneic/xenograft models for evaluation of anti-cancer agents. The firm also customizes In vivo drug metabolism and pharmacokinetics (DMPK) studies to help profile drug candidate in both rodent and non-rodent animal models.

Frequently asked questions about Vivo Bio Tech

Converted at the current exchange rate, the Vivo Bio Tech share trades at 0.14 EUR (14.88 INR).

The revenue of Vivo Bio Tech is 533.35 M INR. This figure is based on current financial data and reflects the company's business performance.

The profit of Vivo Bio Tech is -17.09 M INR. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Vivo Bio Tech is currently -19.32. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Vivo Bio Tech stock.

The price-to-sales ratio (P/S) of Vivo Bio Tech is currently 0.62. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Vivo Bio Tech stock.

The Eulerpool Quality Score for Vivo Bio Tech is 3/10.

The ISIN of Vivo Bio Tech is INE380K01017. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Vivo Bio Tech is 511509.BO. The ticker symbol is used to trade Vivo Bio Tech shares on the stock exchange.

Fair ValueTerminal
12.95 INR
Over-/UndervaluationTerminal
Fairly valued
Sector
—
Industry
Other
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website vivobio.com
Country
Currency
INR
Initial public offering
May 23, 1994
ISIN
INE380K01017
Cusip
Y937AA110
Market capitalization
330.19 M INRSmall Cap
52-Week Range
PEG
—
P/E ratio
P/Ee
—
P/S
P/Se
—
EV/EBIT
7.60
P/B Ratio
0.35
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-1.22 %
Last updated Oct 10, 2026, 9:08 PM

Vivo Bio Tech Peer Group

Vivo Bio Tech FIGI

VIVO:IN · BBG000DGSMT9VIVO:IB · BBG000DGSP21

All fundamentals and in-depth analysis of Vivo Bio Tech

Our stock analysis for Vivo Bio Tech stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Vivo Bio Tech. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.